Melbourne company Prana Biotechnology has announced it has received a R&D Tax Incentive of A$2.5 million to support its scientific focus upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases. The payment is part of approximately A$5.8 million which is expected to be received for the 2011-12 and 2012-13 financial years. “This Australian Government funded program is commendable because it provides significant amounts of non-dilutive cash to support our ongoing research activities.” commented Geoffrey Kempler, Prana’s Chairman and CEO.
ZBB Energy Corporation is an industry leader in the design, development and manufacture of energy storage and power control technology. The company’s Australian subsidiary ZBB Energy Pty has announced an AUS$180,000 R&D Tax Incentive Refund for the 2012 fiscal year. Eric Apfelbach, CEO and President of ZBB Energy said “We appreciate the continued support of the Australian government for our research activities in Australia. Our R&D efforts on new product designs, cost reduction, and performance improvements on our flow battery […]
Australian Biotechnology Company, Spinifex Pharmaceuticals has announced it has received an R&D Tax Incentive of approximately AUS$1.5 million. The Melbourne company established in June 2005 develops new medicinal drugs for the treatment and management of pain. The funds will be reinvested in further clinical development. Spinifex Pharmaceuticals CEO Tom McCarthy said: “This payment under the R&D tax incentive program is a good example of how Government initiatives can support innovative companies in the biotechnology industry and other sectors”. Click here […]
As the R&D Incentive deadline looms, companies are reminded that they need to register before 30 April to be eligible to claim for R&D activities for the 2012 financial year. This is the first year the benefits of the new R&D Tax Incentive will be seen. The R&D Tax Incentive (which replaced the R&D Tax Concession), provides generous support for companies who spent over $20,000 on experimental activities in FY2012. Companies with an aggregated turnover of less $20 million could […]